跳至主要内容
临床试验/NCT05060783
NCT05060783招募中不适用

Renal Cancer Detection With Liquid Biopsy

Zealand University Hospital1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2021年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
200
试验地点
1
主要终点
To identify the optimal GAG score

研究概览

简要总结

Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who underwent CT-scan with suspicion of renal tumor and the scans show no sign of renal cancer.
  • For patient with ccRCC or oncocytoma, they should have a histological verified tumor (Biopsy or surgical specimen)
  • Sign up information consent
  • Can perform protocol procedure

排除标准

  • Non-clear cell Renal cell carcinoma
  • RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney
  • Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively ≤4 weeks will be allowed.

结局指标

主要结局

To identify the optimal GAG score

时间窗: 2 years

To identify the optimal GAG score in healthy individuel

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nessn Azawi

Associate professor

Zealand University Hospital

研究点 (1)

Loading locations...

相似试验